Replimune Group, Inc.
REPLDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
REPL Earnings Report
EPS Est: $-0.66 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How REPL's past catalysts played out
Vusolimogene Oderparepvec
Advanced Melanoma
RP2
Metastatic Uveal Melanoma
RP1
Non-Small Cell Lung Cancer (NSCLC)
RP3
Refractory Metastatic Colorectal Cancer
Cemiplimab
Cutaneous Squamous Cell Carcinoma
RP1, intra-tumoral injection, oncolytic virus
Cutaneous Squamous Cell Carcinoma
RP2 Monotherapy
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vusolimogene Oderparepvec | Phase 3 | Advanced Melanoma | - | - |
RP2 | Phase 3 | Metastatic Uveal Melanoma | - | - |
RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
RP3 | Phase 2 | Refractory Metastatic Colorectal Cancer | - | - |
Cemiplimab | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP1, intra-tumoral injection, oncolytic virus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP2 Monotherapy | Phase 2 | Hepatocellular Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Replimune Group, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Replimune Group, Inc.'s (REPL) pipeline across Phase 3, Phase 2. Its lead program is Vusolimogene Oderparepvec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Replimune Group, Inc.'s next FDA catalyst?→
Replimune Group, Inc.'s (REPL) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REPL biotech catalysts?→
Add REPL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Replimune Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.